Table S2. Description of outcome by each primary diseases

Variable	With polypharmacy	Without polypharmacy	p-value[a]
Injury, poisoning and certain other consequences of external causes	103	27	Polypharmacy (0.003)
FILS at baseline	8.0 (7.0–8.0)	7.0 (7.0–8.0)	Times (<0.001)
FILS at follow-up	8.0 (7.0–8.0)	7.0 (7.0–8.0)	Time×Polypharmacy (0.389)
Cerebrovascular disease	67	45	Polypharmacy (0.852)
FILS at baseline	7.0 (2.0–7.0)	6.0 (2.0–7.0)	Times (<0.001)
FILS at follow-up	8.0 (7.0–8.0)	8.0 (7.0–8.0)	Time×Polypharmacy 0.696
Diseases of the respiratory system	27	16	Polypharmacy (0.095)
FILS at baseline	6.0 (3.0–7.0)	2.5 (1.0–7.0)	Times (0.001)
FILS at follow-up	7.0 (7.0–8.0)	7.0 (4.5–7.25)	Time×Polypharmacy (0.772)
Cancer	11	5	Polypharmacy (0.153)
FILS at baseline	1.0 (1.0–7.0)	1.0 (1.0–1.0)	Times (<0.001)
FILS at follow-up	8.0 (7.0–8.0)	4.0 (4.0–7.0)	Time×Polypharmacy (0.983)

Values are presented as number or median (interquartile range). We defined ≥5 medication usage as polypharmacy.

FILS, Food intake level scale.

[a]Using a two-way ANOVA for Times×Polypharmacy excluded a common condition leading dysphagia as scenario analysis. We selected "Injury, poisoning and certain other consequences of external cause," "Cerebrovascular disease," "Diseases of the respiratory system," and "Cancer" from primary diseases.